Bionexus Gene LabBGLC
13F holders, Q1 2026 (March 31)2holders +1
2new positions
1sold out
$2.14avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, up 1 from Q4 2025. 2 opened new positions and 1 sold out. The largest holders were UBS Group AG ($495) and Wells Fargo & Company ($2).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $497 |
| Exits | 1 | $189K |
All 13F filers, Q4 2025 → Q1 2026: 232 shares bought and 47,830 shares sold, net −47,598 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| UBS Group AG | 0.00% | New | 231 | $495 |
| Wells Fargo & Company | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.